Predictors of long-term cognitive outcome in Alzheimer's disease

Table 2 A comparison of the completer and non-completer groups

	Completers	Non-completers	P- value
Variable	N = 368/44%	N = 475/56%
Female gender	64%	62%	0.614
APOE ε4 carrier	67%	69%	0.652
Estimated age at onset, years^a	71.8 ± 7.4	72.1 ± 7.5	0.513
Age at first assessment, years^a	74.9 ± 7.1	75.0 ± 7.2	0.744
Education, years^a	9.4 ± 2.5	9.4 ± 2.5	0.978
MMSE score at baseline^a	22.3 ± 3.4	20.7 ± 3.9	< 0.001
ADAS-cog score (0 to 70) at baseline^a	18.2 ± 8.3	22.4 ± 8.9	< 0.001
IADL score at baseline^a	14.5 ± 5.3	16.9 ± 5.2	< 0.001
PSMS score at baseline^a	7.0 ± 1.7	7.8 ± 2.3	< 0.001
Number of medications at baseline^a	2.8 ± 2.5	2.8 ± 2.3	0.827
NSAIDs/Acetylsalicylic acid	29%	31%	0.649
ChEI-dose^b	70%	63%	< 0.001

^a Mean ± standard deviation
^bMean percentage of the maximum recommended dose, that is, 10 mg donepezil, 12 mg rivastigmine and 24 mg galantamine.
Abbreviations: ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; APOE, Apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAID, Nonsteroidal anti-inflammatory drugs; PSMS, Physical Self-Maintenance Scale.

ISSN: 1758-9193